A retrospective study evaluating the impact of infectious complications during azacitidine treatment View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-05-04

AUTHORS

Anna Schuck, Marie-Christine Goette, Judith Neukirchen, Andrea Kuendgen, Norbert Gattermann, Thomas Schroeder, Guido Kobbe, Ulrich Germing, Rainer Haas

ABSTRACT

Azacitidine has become an available therapy for high-risk myelodysplastic syndromes. Infectious complications (IC) may impede the success of therapy. Since most patients are managed in an outpatient setting, often with low level of clinical and microbiological documentation, the impact of IC remains unclear. We retrospectively evaluated the clinical course of 77 patients with MDS treated with azacitidine between 2004 and 2015 (median age 69 years). Clinical workup included severity and type of IC, days in the hospital and with antimicrobial therapy, response to azacitidine, and overall survival (OS). In total, 614 azacitidine cycles were administered, 81 cycles with at least one IC. The median number of administered cycles was 6 (range 1–43). Median OS after the start of azacitidine was 17 months (range 1–103). Infection rates were higher in the first 3 cycles with bacterial infections leading. The better patients’ hematological response to azacitidine with less IC occurred, and fewer days with antimicrobial treatment were needed. Compared to progressive disease, stable disease made no significant improvement in occurrence of IC and days in the hospital. Older age was associated with more IC and longer time in the hospital. Comorbidities or IPSS-R had no influence on IC. The incidence of IC correlated with hematological response and age. Stable disease led to longer OS, but incidence of IC was comparable to progressive disease and survival seemed to be bought by a considerable number of IC. IC rates were highest in the first 3 cycles. We recommend response evaluation after 4–6 cycles. More... »

PAGES

1097-1104

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2

DOI

http://dx.doi.org/10.1007/s00277-017-3001-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1085177784

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28474144


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Infective Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azacitidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bacterial Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Length of Stay", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outcome Assessment, Health Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schuck", 
        "givenName": "Anna", 
        "id": "sg:person.07532014665.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07532014665.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goette", 
        "givenName": "Marie-Christine", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neukirchen", 
        "givenName": "Judith", 
        "id": "sg:person.0643404664.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuendgen", 
        "givenName": "Andrea", 
        "id": "sg:person.01022105364.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022105364.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gattermann", 
        "givenName": "Norbert", 
        "id": "sg:person.01273447501.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schroeder", 
        "givenName": "Thomas", 
        "id": "sg:person.01271136615.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271136615.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kobbe", 
        "givenName": "Guido", 
        "id": "sg:person.01164073234.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164073234.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germing", 
        "givenName": "Ulrich", 
        "id": "sg:person.01362464041.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haas", 
        "givenName": "Rainer", 
        "id": "sg:person.01127414674.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00277-016-2649-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038586565", 
          "https://doi.org/10.1007/s00277-016-2649-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01703109", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036298304", 
          "https://doi.org/10.1007/bf01703109"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-05-04", 
    "datePublishedReg": "2017-05-04", 
    "description": "Azacitidine has become an available therapy for high-risk myelodysplastic syndromes. Infectious complications (IC) may impede the success of therapy. Since most patients are managed in an outpatient setting, often with low level of clinical and microbiological documentation, the impact of IC remains unclear. We retrospectively evaluated the clinical course of 77 patients with MDS treated with azacitidine between 2004 and 2015 (median age 69\u00a0years). Clinical workup included severity and type of IC, days in the hospital and with antimicrobial therapy, response to azacitidine, and overall survival (OS). In total, 614 azacitidine cycles were administered, 81\u00a0cycles with at least one IC. The median number of administered cycles was 6 (range 1\u201343). Median OS after the start of azacitidine was 17\u00a0months (range 1\u2013103). Infection rates were higher in the first 3 cycles with bacterial infections leading. The better patients\u2019 hematological response to azacitidine with less IC occurred, and fewer days with antimicrobial treatment were needed. Compared to progressive disease, stable disease made no significant improvement in occurrence of IC and days in the hospital. Older age was associated with more IC and longer time in the hospital. Comorbidities or IPSS-R had no influence on IC. The incidence of IC correlated with hematological response and age. Stable disease led to longer OS, but incidence of IC was comparable to progressive disease and survival seemed to be bought by a considerable number of IC. IC rates were highest in the first 3 cycles. We recommend response evaluation after 4\u20136\u00a0cycles.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-017-3001-2", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "96"
      }
    ], 
    "keywords": [
      "incidence of IC", 
      "infectious complications", 
      "overall survival", 
      "hematological response", 
      "stable disease", 
      "high-risk myelodysplastic syndrome", 
      "more infectious complications", 
      "median overall survival", 
      "longer overall survival", 
      "success of therapy", 
      "azacitidine cycles", 
      "microbiological documentation", 
      "most patients", 
      "clinical course", 
      "azacitidine treatment", 
      "myelodysplastic syndrome", 
      "clinical workup", 
      "retrospective study", 
      "available therapies", 
      "outpatient setting", 
      "antimicrobial therapy", 
      "median number", 
      "azacitidine", 
      "infection rate", 
      "antimicrobial treatment", 
      "bacterial infections", 
      "older age", 
      "hospital", 
      "disease", 
      "response evaluation", 
      "therapy", 
      "complications", 
      "IC rates", 
      "patients", 
      "incidence", 
      "survival", 
      "age", 
      "days", 
      "treatment", 
      "significant improvement", 
      "low levels", 
      "comorbidities", 
      "response", 
      "IPSS", 
      "syndrome", 
      "workup", 
      "infection", 
      "considerable number", 
      "severity", 
      "months", 
      "rate", 
      "MDS", 
      "setting", 
      "course", 
      "levels", 
      "long time", 
      "evaluation", 
      "start", 
      "study", 
      "number", 
      "occurrence", 
      "impact", 
      "cycle", 
      "improvement", 
      "documentation", 
      "types", 
      "success", 
      "time", 
      "influence"
    ], 
    "name": "A retrospective study evaluating the impact of infectious complications during azacitidine treatment", 
    "pagination": "1097-1104", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1085177784"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-017-3001-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28474144"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-017-3001-2", 
      "https://app.dimensions.ai/details/publication/pub.1085177784"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_750.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-017-3001-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2'


 

This table displays all metadata directly associated to this object as RDF triples.

261 TRIPLES      21 PREDICATES      113 URIs      103 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-017-3001-2 schema:about N1b5502741a19426d9d5ab3a4248cbacc
2 N1e05ce55025746f4bc78551ea1240571
3 N1e7976e309104cb4b3ac3607fbf26e50
4 N1ebdcf4238614c60bc88cb505c5a305d
5 N26e83c49191149bd8d33ecce181dfb44
6 N3ff01f2426aa4a5dbe13834f5bc98853
7 N4f55d4a2ab2c4c2ab5228f320a17d513
8 N663f6cb98a024642af9ada2a54b13f52
9 N793a8cc29de64bdf80dc8d0d46c13ddd
10 N7cceeb9ac34942cc99fa4d812e8fc946
11 N8804089f5c284000b772e15da8236371
12 N88673e581cdd42ccb63ea9cb9d313edc
13 N88835862029c42a19224cc39804a7d20
14 N8cd967f204564c46aeaadf466625feaa
15 N94a744be15024053be46a5f54b069fc8
16 Na9ddbcff717542babd1c7ccf121b0c64
17 Ne134cdfaa4404fa4aa863a69516d207a
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author N9b2fe15ead4d4ae6ac909e63d6d1ddd3
21 schema:citation sg:pub.10.1007/bf01703109
22 sg:pub.10.1007/s00277-016-2649-3
23 schema:datePublished 2017-05-04
24 schema:datePublishedReg 2017-05-04
25 schema:description Azacitidine has become an available therapy for high-risk myelodysplastic syndromes. Infectious complications (IC) may impede the success of therapy. Since most patients are managed in an outpatient setting, often with low level of clinical and microbiological documentation, the impact of IC remains unclear. We retrospectively evaluated the clinical course of 77 patients with MDS treated with azacitidine between 2004 and 2015 (median age 69 years). Clinical workup included severity and type of IC, days in the hospital and with antimicrobial therapy, response to azacitidine, and overall survival (OS). In total, 614 azacitidine cycles were administered, 81 cycles with at least one IC. The median number of administered cycles was 6 (range 1–43). Median OS after the start of azacitidine was 17 months (range 1–103). Infection rates were higher in the first 3 cycles with bacterial infections leading. The better patients’ hematological response to azacitidine with less IC occurred, and fewer days with antimicrobial treatment were needed. Compared to progressive disease, stable disease made no significant improvement in occurrence of IC and days in the hospital. Older age was associated with more IC and longer time in the hospital. Comorbidities or IPSS-R had no influence on IC. The incidence of IC correlated with hematological response and age. Stable disease led to longer OS, but incidence of IC was comparable to progressive disease and survival seemed to be bought by a considerable number of IC. IC rates were highest in the first 3 cycles. We recommend response evaluation after 4–6 cycles.
26 schema:genre article
27 schema:isAccessibleForFree false
28 schema:isPartOf N177bc0076aab427aab00e689d25cf484
29 N75c9b79729a14a8d90c9e9d5053c12b8
30 sg:journal.1358129
31 schema:keywords IC rates
32 IPSS
33 MDS
34 age
35 antimicrobial therapy
36 antimicrobial treatment
37 available therapies
38 azacitidine
39 azacitidine cycles
40 azacitidine treatment
41 bacterial infections
42 clinical course
43 clinical workup
44 comorbidities
45 complications
46 considerable number
47 course
48 cycle
49 days
50 disease
51 documentation
52 evaluation
53 hematological response
54 high-risk myelodysplastic syndrome
55 hospital
56 impact
57 improvement
58 incidence
59 incidence of IC
60 infection
61 infection rate
62 infectious complications
63 influence
64 levels
65 long time
66 longer overall survival
67 low levels
68 median number
69 median overall survival
70 microbiological documentation
71 months
72 more infectious complications
73 most patients
74 myelodysplastic syndrome
75 number
76 occurrence
77 older age
78 outpatient setting
79 overall survival
80 patients
81 rate
82 response
83 response evaluation
84 retrospective study
85 setting
86 severity
87 significant improvement
88 stable disease
89 start
90 study
91 success
92 success of therapy
93 survival
94 syndrome
95 therapy
96 time
97 treatment
98 types
99 workup
100 schema:name A retrospective study evaluating the impact of infectious complications during azacitidine treatment
101 schema:pagination 1097-1104
102 schema:productId N11eb78c61f6f4194b581d12a8e2b5a2f
103 N739324a49ac4413ab559cc9343a36181
104 N94afb5a1065a42c89aa72b976b288a65
105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085177784
106 https://doi.org/10.1007/s00277-017-3001-2
107 schema:sdDatePublished 2022-08-04T17:06
108 schema:sdLicense https://scigraph.springernature.com/explorer/license/
109 schema:sdPublisher N9ba8a48109a44586a10d23e34b3c0cb9
110 schema:url https://doi.org/10.1007/s00277-017-3001-2
111 sgo:license sg:explorer/license/
112 sgo:sdDataset articles
113 rdf:type schema:ScholarlyArticle
114 N0fb340cc3179437393d3b6f4bb33db8e rdf:first sg:person.01164073234.53
115 rdf:rest N1d68d127c87b4ba1a70e955264ebd25e
116 N11eb78c61f6f4194b581d12a8e2b5a2f schema:name doi
117 schema:value 10.1007/s00277-017-3001-2
118 rdf:type schema:PropertyValue
119 N13a8d3e4d50541a4bb352c9758653e48 rdf:first sg:person.01127414674.14
120 rdf:rest rdf:nil
121 N177bc0076aab427aab00e689d25cf484 schema:issueNumber 7
122 rdf:type schema:PublicationIssue
123 N1b5502741a19426d9d5ab3a4248cbacc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Kaplan-Meier Estimate
125 rdf:type schema:DefinedTerm
126 N1d68d127c87b4ba1a70e955264ebd25e rdf:first sg:person.01362464041.20
127 rdf:rest N13a8d3e4d50541a4bb352c9758653e48
128 N1e05ce55025746f4bc78551ea1240571 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Outcome Assessment, Health Care
130 rdf:type schema:DefinedTerm
131 N1e7976e309104cb4b3ac3607fbf26e50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Humans
133 rdf:type schema:DefinedTerm
134 N1ebdcf4238614c60bc88cb505c5a305d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Bacterial Infections
136 rdf:type schema:DefinedTerm
137 N26e83c49191149bd8d33ecce181dfb44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Aged, 80 and over
139 rdf:type schema:DefinedTerm
140 N39787a53197746d7987a5ce47799e451 rdf:first sg:person.0643404664.08
141 rdf:rest Nb235fb97af7e4fd396e4a2455078f492
142 N3ff01f2426aa4a5dbe13834f5bc98853 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Risk Factors
144 rdf:type schema:DefinedTerm
145 N474d5d2db33d4c77bdb30dd0212d3ba0 rdf:first N8598f7c7636545b2946f1fadef5683bd
146 rdf:rest N39787a53197746d7987a5ce47799e451
147 N4f55d4a2ab2c4c2ab5228f320a17d513 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Length of Stay
149 rdf:type schema:DefinedTerm
150 N663f6cb98a024642af9ada2a54b13f52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Myelodysplastic Syndromes
152 rdf:type schema:DefinedTerm
153 N739324a49ac4413ab559cc9343a36181 schema:name pubmed_id
154 schema:value 28474144
155 rdf:type schema:PropertyValue
156 N75c9b79729a14a8d90c9e9d5053c12b8 schema:volumeNumber 96
157 rdf:type schema:PublicationVolume
158 N793a8cc29de64bdf80dc8d0d46c13ddd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Retrospective Studies
160 rdf:type schema:DefinedTerm
161 N7cceeb9ac34942cc99fa4d812e8fc946 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Aged
163 rdf:type schema:DefinedTerm
164 N8598f7c7636545b2946f1fadef5683bd schema:affiliation grid-institutes:grid.411327.2
165 schema:familyName Goette
166 schema:givenName Marie-Christine
167 rdf:type schema:Person
168 N8804089f5c284000b772e15da8236371 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Anti-Infective Agents
170 rdf:type schema:DefinedTerm
171 N88673e581cdd42ccb63ea9cb9d313edc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Female
173 rdf:type schema:DefinedTerm
174 N88835862029c42a19224cc39804a7d20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Male
176 rdf:type schema:DefinedTerm
177 N8cd967f204564c46aeaadf466625feaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Azacitidine
179 rdf:type schema:DefinedTerm
180 N94a744be15024053be46a5f54b069fc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Antimetabolites, Antineoplastic
182 rdf:type schema:DefinedTerm
183 N94afb5a1065a42c89aa72b976b288a65 schema:name dimensions_id
184 schema:value pub.1085177784
185 rdf:type schema:PropertyValue
186 N9b2fe15ead4d4ae6ac909e63d6d1ddd3 rdf:first sg:person.07532014665.37
187 rdf:rest N474d5d2db33d4c77bdb30dd0212d3ba0
188 N9ba8a48109a44586a10d23e34b3c0cb9 schema:name Springer Nature - SN SciGraph project
189 rdf:type schema:Organization
190 Na9ddbcff717542babd1c7ccf121b0c64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Adult
192 rdf:type schema:DefinedTerm
193 Nb235fb97af7e4fd396e4a2455078f492 rdf:first sg:person.01022105364.01
194 rdf:rest Nb596071257fe4bb38bc98358ae8be15e
195 Nb578b308d2fc4493a4c90a81ba8b2fae rdf:first sg:person.01271136615.68
196 rdf:rest N0fb340cc3179437393d3b6f4bb33db8e
197 Nb596071257fe4bb38bc98358ae8be15e rdf:first sg:person.01273447501.34
198 rdf:rest Nb578b308d2fc4493a4c90a81ba8b2fae
199 Ne134cdfaa4404fa4aa863a69516d207a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Middle Aged
201 rdf:type schema:DefinedTerm
202 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
203 schema:name Medical and Health Sciences
204 rdf:type schema:DefinedTerm
205 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
206 schema:name Clinical Sciences
207 rdf:type schema:DefinedTerm
208 sg:journal.1358129 schema:issn 0939-5555
209 1432-0584
210 schema:name Annals of Hematology
211 schema:publisher Springer Nature
212 rdf:type schema:Periodical
213 sg:person.01022105364.01 schema:affiliation grid-institutes:grid.411327.2
214 schema:familyName Kuendgen
215 schema:givenName Andrea
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022105364.01
217 rdf:type schema:Person
218 sg:person.01127414674.14 schema:affiliation grid-institutes:grid.411327.2
219 schema:familyName Haas
220 schema:givenName Rainer
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14
222 rdf:type schema:Person
223 sg:person.01164073234.53 schema:affiliation grid-institutes:grid.411327.2
224 schema:familyName Kobbe
225 schema:givenName Guido
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164073234.53
227 rdf:type schema:Person
228 sg:person.01271136615.68 schema:affiliation grid-institutes:grid.411327.2
229 schema:familyName Schroeder
230 schema:givenName Thomas
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271136615.68
232 rdf:type schema:Person
233 sg:person.01273447501.34 schema:affiliation grid-institutes:grid.411327.2
234 schema:familyName Gattermann
235 schema:givenName Norbert
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34
237 rdf:type schema:Person
238 sg:person.01362464041.20 schema:affiliation grid-institutes:grid.411327.2
239 schema:familyName Germing
240 schema:givenName Ulrich
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20
242 rdf:type schema:Person
243 sg:person.0643404664.08 schema:affiliation grid-institutes:grid.411327.2
244 schema:familyName Neukirchen
245 schema:givenName Judith
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08
247 rdf:type schema:Person
248 sg:person.07532014665.37 schema:affiliation grid-institutes:grid.411327.2
249 schema:familyName Schuck
250 schema:givenName Anna
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07532014665.37
252 rdf:type schema:Person
253 sg:pub.10.1007/bf01703109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036298304
254 https://doi.org/10.1007/bf01703109
255 rdf:type schema:CreativeWork
256 sg:pub.10.1007/s00277-016-2649-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038586565
257 https://doi.org/10.1007/s00277-016-2649-3
258 rdf:type schema:CreativeWork
259 grid-institutes:grid.411327.2 schema:alternateName Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstraße 5, 40225, Düsseldorf, Germany
260 schema:name Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstraße 5, 40225, Düsseldorf, Germany
261 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...